enVVeno Medical Corporation - Common Stock, $0.00001 par value (NVNO)

CUSIP: 29415J106

Q4 2025 13F Holders as of 31 Dec 2025

Type / Class
Equity / Common Stock, $0.00001 par value
Shares outstanding
685,936
Total 13F shares
6,556,240
Share change
+494,377
Total reported value
$2,102,925
Price per share
$0.32
Number of holders
36
Value change
+$127,120
Number of buys
14
Number of sells
14

Security key

29415J106

Report period

Q4 2025

Institutions

36

Top holders

10

Top shareholders of NVNO - enVVeno Medical Corporation - Common Stock, $0.00001 par value (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Holder Source Role / Reporting Ownership % Shares Holdings Value 12M Net Δ As of Details
Thomas A. Satterfield Jr.
13D/G
9%
1,822,500
$1,348,650 $0 14 Nov 2025
Nantahala Capital Management, LLC
13D/G
3.5%
688,940
$624,180 -$540,807 30 Sep 2025
PERCEPTIVE ADVISORS LLC
13F
Company
256%
1,759,035
$1,593,686 30 Sep 2025
13F
KINGDON CAPITAL MANAGEMENT, L.L.C.
13F
Company
198%
1,359,261
$1,231,626 30 Sep 2025
13F
VANGUARD GROUP INC
13F
Company
126%
861,191
$780,239 30 Sep 2025
13F
CM Management, LLC
13F
Company
87%
600,000
$543,660 30 Sep 2025
13F
Westside Investment Management, Inc.
13F
Company
31%
212,800
$192,816 30 Sep 2025
13F
GEODE CAPITAL MANAGEMENT, LLC
13F
Company
29%
201,244
$182,368 30 Sep 2025
13F
JPMORGAN CHASE & CO
13F
Company
27%
182,322
$165,202 30 Sep 2025
13F
SUSQUEHANNA INTERNATIONAL GROUP, LLP
13F
Company
23%
154,471
$139,966 30 Sep 2025
13F
JANE STREET GROUP, LLC
13F
Company
10%
71,771
$65,032 30 Sep 2025
13F
BlackRock, Inc.
13F
Company
8.7%
59,857
$54,236 30 Sep 2025
13F
HRT FINANCIAL LP
13F
Company
8%
55,135
$49,000 30 Sep 2025
13F
CITADEL ADVISORS LLC
13F
Company
8%
54,811
$49,664 30 Sep 2025
13F
XTX Topco Ltd
13F
Company
6.1%
42,042
$38,094 30 Sep 2025
13F
STATE STREET CORP
13F
Company
5.9%
40,800
$36,969 30 Sep 2025
13F
MARSHALL WACE, LLP
13F
Company
5.8%
39,883
$36,294 30 Sep 2025
13F
Creative Planning
13F
Company
5.6%
38,295
$34,699 30 Sep 2025
13F
NORTHERN TRUST CORP
13F
Company
5.6%
38,081
$34,505 30 Sep 2025
13F
Fermata Advisors, LLC
13F
Company
5.5%
37,449
$33,933 30 Sep 2025
13F
RENAISSANCE TECHNOLOGIES LLC
13F
Company
4.3%
29,200
$26,458 30 Sep 2025
13F
AQR CAPITAL MANAGEMENT LLC
13F
Company
3.3%
22,832
$20,688 30 Sep 2025
13F
WOLVERINE TRADING, LLC
13F
Company
2.7%
18,339
$17,204 30 Sep 2025
13F
TWO SIGMA SECURITIES, LLC
13F
Company
2.1%
14,111
$12,786 30 Sep 2025
13F
Tamar Securities, LLC
13F
Company
2%
13,990
$12,677 30 Sep 2025
13F
SIMPLEX TRADING, LLC
13F
Company
2%
13,751
$12,000 30 Sep 2025
13F
GSA CAPITAL PARTNERS LLP
13F
Company
2%
13,420
$12,000 30 Sep 2025
13F
Sanctuary Advisors, LLC
13F
Company
1.7%
12,000
$31,560 30 Sep 2025
13F
UBS Group AG
13F
Company
1.5%
10,270
$9,305 30 Sep 2025
13F
Cambridge Investment Research Advisors, Inc.
13F
Company
1.5%
10,001
$9,000 30 Sep 2025
13F
MORGAN STANLEY
13F
Company
0.54%
3,720
$3,371 30 Sep 2025
13F
WELLS FARGO & COMPANY/MN
13F
Company
0.29%
2,000
$1,812 30 Sep 2025
13F
Avion Wealth
13F
Company
0.29%
2,000
$1,000 30 Sep 2025
13F
WOLVERINE ASSET MANAGEMENT LLC
13F
Company
0.26%
1,768
$1,601 30 Sep 2025
13F
CIBC Private Wealth Group LLC
13F
Company
0.13%
860
$779 30 Sep 2025
13F
OSAIC HOLDINGS, INC.
13F
Company
0.04%
250
$232 30 Sep 2025
13F
GROUP ONE TRADING LLC
13F
Company
0.03%
202
$183 30 Sep 2025
13F
JONES FINANCIAL COMPANIES LLLP
13F
Company
0%
20
$19 30 Sep 2025
13F
BANK OF AMERICA CORP /DE/
13F
Company
0%
20
$18 30 Sep 2025
13F
Matthew M. Jenusaitis
3/4/5
Director
mixed-class rows
152,428
mixed-class rows
$41,859 11 Dec 2025
Robert Gray
3/4/5
Director
mixed-class rows
147,038
mixed-class rows
$32,796 11 Dec 2025
Sanjay Shrivastava
3/4/5
Director
mixed-class rows
145,171
mixed-class rows
$26,935 11 Dec 2025
Robert A. Berman
3/4/5
Chief Executive Officer, Director
mixed-class rows
222,236
mixed-class rows
$7,560 16 Dec 2025
Marc H. Glickman
3/4/5
SVP & Chief Medical Officer
mixed-class rows
76,600
mixed-class rows
$544 16 Dec 2025
Jennifer Bright
3/4/5
Chief Financial Officer
class O/S missing
350,000
19 May 2025
Craig Glynn
3/4/5
Chief Financial Officer
class O/S missing
75,000
05 Dec 2023
Hamed Alavi
3/4/5
Chief Technology Officer
class O/S missing
75,000
16 Dec 2025

Institutional Holders of enVVeno Medical Corporation - Common Stock, $0.00001 par value (NVNO) as of Q4 2025

As of 31 Dec 2025, enVVeno Medical Corporation - Common Stock, $0.00001 par value (NVNO) was held by 36 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 6,556,240 shares. The largest 10 holders included PERCEPTIVE ADVISORS LLC, KINGDON CAPITAL MANAGEMENT, L.L.C., CM Management, LLC, VANGUARD GROUP INC, GEODE CAPITAL MANAGEMENT, LLC, GSA CAPITAL PARTNERS LLP, JPMORGAN CHASE & CO, JANE STREET GROUP, LLC, TWO SIGMA INVESTMENTS, LP, and SUSQUEHANNA INTERNATIONAL GROUP, LLP. This page lists 36 institutional shareholders reporting positions in this security for the Q4 2025 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period

Compare Q4 2025 vs Q3 2025 Across Filers

Q3 2025 holders
36
Q4 2025 holders
36
Holder diff
0
Investor Q3 2025 Shares Q4 2025 Shares Share Diff Share Chg % Q3 2025 Value $ Q4 2025 Value $ Value Diff $ Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .